bpc 157 and nad nad+ vs Why would a patient trust a peptide more than a statin? How Functional Medicine Approaches Transform – Skn Elements - Unlock the

Tkalcevi VI, Cuzi S, Brajsa K, Mildner B, Bokuli A, Situm K, et al

Wang et al., 2014

Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions

AK, CeFra